| 15981/34347 | US=6 / Quimioterapia Airley R. Classical anticancer agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 67-115. ISBN 978-0-470-09254-5. CLASSICOS AGENTES ANTICANCERIGENOS; AGENTE SUILANTES; ANTIMETABOLITOS; ANTIBIOTICOS ANTITUMORAIS; PRODROGAS ANTRACICLINA; SULCO DE LIGACAO DE AGENTES; INIBIDORES DA TOPOISOMERASE; INIBIDORES MITOTICOS; HORMONAIS AGENTES ANTICANCERIGENOS; REGIMES DE QUIMIOTERAPIA |
| 15982/34347 | US=6 / Quimioterapia Airley R. The philosophy of cancer research. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 117-23. ISBN 978-0-470-09254-5. PESQUISA DO CANCER; PESQUISA DO CANCER NO REINO UNIDO; PESQUISA SOBRE O CANCER NOS ESTADOS UNIDOS |
| 15983/34347 | US=6 / Quimioterapia Airley R. Novel anticancer agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 125-65. ISBN 978-0-470-09254-5. AGENTES ANTICANCERIGENOS; MANIPULACAO GENETICA DE LINHAS CELULARES; CELULAS TUMORAIS SHEROIDS; DROGAS DE CHUMBO; TRIAGEM; ATIVIDADE ANTICANCERIGENA IN VITRO; XENOENXERTOS TUMORES |
| 15984/34347 | US=6 / Quimioterapia Airley R. Clinical trials. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 167-75. ISBN 978-0-470-09254-5. EVOLUCAO NO TRATAMENTO; ENSAIOS CLINICOS; AVALIACAO DA VASCULARIZACAO; ANGIOGENESE PELA TECNOLOGIA DE MEDICINA NUCLEAR |
| 15985/34347 | US=6 / Quimioterapia Airley R. Tumour hypoxia. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 177-98. ISBN 978-0-470-09254-5. |
| 15986/34347 | US=6 / Quimioterapia Airley R. Antiangiogenic and antivascular agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 199-216. ISBN 978-0-470-09254-5. AGENTES ANTIANGIOGENICOS; AGENTES ANTIVASCULAR; HISTORIA DA ANGIOGENESE; ANTI-ANGIOGENICOS; TALIDOMIDA; ANTICORPOS; AGENTES ANTIANGIOGENICOS; AGENTES PERTURBADORES |
| 15987/34347 | US=6 / Quimioterapia Airley R. Tyrosine kinase inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 217-23. ISBN 978-0-470-09254-5. INIBIDORES DA QUINASE DE TIROSINA; NAO-RECEPTOR INIBIDORES DE TIROSINA |
| 15988/34347 | US=6 / Quimioterapia Airley R. Ras inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 225-8. ISBN 978-0-470-09254-5. |
| 15989/34347 | US=6 / Quimioterapia Airley R. Inhibitors of the AKT/PKB pathway. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 229-31. ISBN 978-0-470-09254-5. |
| 15990/34347 | US=6 / Quimioterapia Airley R. Targeting stress proteins: HSP90 inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 233-6. ISBN 978-0-470-09254-5. |
| 15991/34347 | US=6 / Quimioterapia Airley R. The proteasome. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 237-43. ISBN 978-0-470-09254-5. |
| 15992/34347 | US=6 / Quimioterapia Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5. CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR |
| 15993/34347 | US=6 / Quimioterapia Airley R. Telomerase. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 249-54. ISBN 978-0-470-09254-5. |
| 15994/34347 | US=6 / Quimioterapia Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5. INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA |
| 15995/34347 | US=6 / Quimioterapia Airley R. Pharmaceutical problems in cancer chemotherapy. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 265-80. ISBN 978-0-470-09254-5. PROBLEMAS FARMACEUTICOS EM QUIMIOTERAPIA; MANIFESTACAO DE TOXICIDADE; REGIME DE TOXICIDADE; RESISTENCIA A DROGAS; COMPLICACOES FARMACEUTICAS |
| 15996/34347 | US=6 / Quimioterapia Airley R. Oncology pharmacy at home and abroad. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 281-2. ISBN 978-0-470-09254-5. |
| 15997/34347 | US=6 / Quimioterapia Airley R. Practice exam questions. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 283-98. ISBN 978-0-470-09254-5. |
| 15998/34347 | US=22 / Urologia Bukowski RM, Figlin RA, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma: overview. In: ___. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 1-12. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; VHL GENE; PROTEINA VHL; VEGF; PDGF; TERAPIAS RCC |
| 15999/34347 | US=22 / Urologia Dhanani N, Vocke C, Bratslavsky G, Linehan WM. Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 13-33. ISBN 978-1-58829-737-2. NEOPLASIAS DE RIM; HIPPLE CON-LINDAU; BHD; BIRT-HOGG-DUBE; FUMARATO HIDRATASE |
| 16000/34347 | US=22 / Urologia Zhou M. Molecular targets in renal tumors: pathologic assessment. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 35-48. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; NEOPLASIA RENAL PATOLOGIA; CITOGENETICA; PROGNOSTICO |